LifeMine Therapeutics has closed $263 million in financing to accelerate clinical trials of LIFE-001, a novel immunosuppressant drug discovered through fungal genomics.

Researchers at the University of Vienna are developing "mycomining": using fungi to extract rare earth elements from contaminated industrial sites and waste materials